Journal
JOURNAL OF SPINAL DISORDERS & TECHNIQUES
Volume 16, Issue 2, Pages 113-122Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/00024720-200304000-00001
Keywords
anterior lumbar interbody fusion; INFUSE Bone Graft; bone morphogenetic protein; fusion cage; degenerative disc disease; lumbar spine; rhBMP-2
Categories
Ask authors/readers for more resources
Multicenter human clinical studies of patients undergoing anterior lumbar fusion have been conducted using recombinant bone morphogenetic protein or rhBMP-2 on an absorbable collagen sponge, marketed as INFUSE Bone Graft, or autograft implanted in the LT-CAGE Lumbar Tapered Fusion device. An integrated analysis of multiple clinical studies was performed using an analysis of covariance to adjust for preoperative variables in a total of 679 patients. Of these patients, 277 had their cages implanted with rhBMP-2 on an absorbable collagen sponge and 402 received autograft transferred from the iliac crest. The patients treated with rhBMP-2 had statistically superior outcomes with regard to length of surgery, blood loss, hospital stay, reoperation rate, median time to return to work, and fusion rates at 6, 12, and 24 months. Oswestry Disability Index scores and the Physical Component Scores and Pain Index of the SF-36 scale at 3, 6, 12, and 24 months showed statistically superior outcomes in the rhBMP-2 group.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available